Research Publications
2019
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Mittal D, Lepletier A, Madore J, Aguilera A, Stannard K, Blake S et al. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research. 2019;7(4):559-571.
Reflectance Confocal Microscopy made easy: the four must-know key features for the diagnosis of melanoma and non-melanoma skin cancers
Pellacani G, Scope A, Gonzalez S, Guitera P, Farnetani F, Malvehy J et al. Reflectance Confocal Microscopy made easy: the four must-know key features for the diagnosis of melanoma and non-melanoma skin cancers. Journal of the American Academy of Dermatology. 2019.
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Jansen Y, Rozeman E, Mason R, Goldinger S, Geukes Foppen M, Hoejbergs L et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology. 2019.
Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials.
Edwards J, Tasker A, Silva I, Quek C, Batten M, Ferguson A et al. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials. Clinical Cancer Research. 2019.
False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.
Nijhuis A, Dieng M, Khanna N, Lord S, Dalton J, Menzies A et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology. 2019.
Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients
Nijhuis A, de A.O. Santos Filho I, Uren R, Thompson J, Nieweg O. Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients. European Journal of Surgical Oncology. 2019.
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
Heinzerling L, Ascierto P, Dummer R, Gogas H, Grob J, Lebbe C et al. Adverse events 2.0—Let us get SERIOs. European Journal of Cancer. 2019;112:29-31.
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
Hong A, Ferguson P, Dodds T, Jones D, Li M, Yang J et al. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncology. 2019;92:33-39.
Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.
Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.
Dessinioti C, Dimou N, Geller A, Stergiopoulou A, Lo S, Keim U et al. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. JNCI: Journal of the National Cancer Institute. 2019.
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Lee J, Saw R, Thompson J, Lo S, Spillane A, Shannon K et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology. 2019.
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology. 2019;37(11):867-875.
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. 2019.
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019.
Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
Quek C, Rawson R, Ferguson P, Shang P, Silva I, Saw R et al. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget. 2019;10(9).
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.
Kim H, Duong J, Gonzalez M, Long G, Menzies A, Rizos H et al. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology. 2019.